Top

International Journal of Clinical Oncology

Published in:

01-04-2020 | Metastasis | Original Article

Impact of microscopically margin-positive resection on survival in children with hepatoblastoma after hepatectomy: a retrospective cohort study

Authors: Xianghai Ren, Haibo Li, Mei Diao, Hang Xu, Long Li

Published in: International Journal of Clinical Oncology | Issue 4/2020

Abstract

Background

Impact of R1 (microscopically margin-positive) resection on survival of patients with hepatoblastoma (HB) remains debatable. This study aimed to compare the long-term outcomes of R0 (microscopically margin-negative) and R1 resection for HB in children after hepatectomy.

Methods

We retrospectively reviewed files of children with HB who underwent resection at our institution between September 1, 2005, and November 30, 2017. Survival analyses and prognostic factors were evaluated using Kaplan–Meier curves and Cox regression models.

Results

Of 259 patients, 218 (84.2%) underwent R0 and 41 (15.8%) R1 resection. After adjusting for confounding factors, R1 resection demonstrated non-significantly lower overall survival (OS: hazard ratio [HR] = 0.75; 95% CI 0.34–1.64) and shorter event-free survival (EFS: HR = 0.97; 95% CI 0.53–1.78) rates than R0 resection. However, stratified analysis showed significantly increased risk of poor OS and EFS in patients with metastasis and mixed epithelial/mesenchymal pathologic subtype in R1 compared with R0 resection (P values for interactions < 0.05). There was no significant difference between R0 resection with metastasis and R1 resection with metastasis in the incidence of local recurrence (P = 0.494); however, a significant difference in the incidence of local recurrence was seen between R0 and R1 resection for subgroups with mixed pathologic subtypes (P = 0.035).

Conclusions

With effective chemotherapy, microscopic margin status may not be associated with survival outcome in children with HB undergoing hepatectomy. However, stratified analysis showed that R1 resection might be associated with decreased survival in children with mixed epithelial/mesenchymal HB, compared with R0 resection, and not affect survival outcomes in those with an epithelial subtype and without metastasis.

Available only for authorised users

Hung GY, Lin LY, Yu TY et al (2018) Hepatoblastoma incidence in Taiwan: a population-based study. J Chin Med Assoc 81:541–547CrossRef

Aronson DC, Meyers RL (2016) Malignant tumors of the liver in children. Sem Pedatr Surg 25:265–275CrossRef

Hishiki T, Matsunaga T, Sasaki F et al (2011) Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT. Pediatr Surg Int 27:1–8CrossRef

Haeberle B, Dv S (2012) Treatment of hepatoblastoma in the German cooperative pediatric liver tumor studies. Front Biosci 4:493–498CrossRef

Fahy AS, Shaikh F, Gerstle JT (2019) Multifocal hepatoblastoma: what is the risk of recurrent disease in the remnant liver? J Pediatr Surg. https://doi.org/10.1016/j.jpedsurg.2019.01.036 CrossRefPubMed

Yuan XJ, Wang HM, Jiang H et al (2016) Multidisciplinary effort in treating children with hepatoblastoma in China. Cancer Lett 375:39–46CrossRef

Fuchs J, Rydzynski J, Dietrich VS et al (2002) Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 95:172–182CrossRef

Pham TA, Gallo AM, Concepcion W et al (2015) Effect of liver transplant on long-term disease-free survival in children with hepatoblastoma and hepatocellular cancer. JAMA Surg 150:1150–1158CrossRef

Meyers RL, Tiao G, De Goyet JD et al (2014) Hepatoblastoma state of the art: pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation. Curr Opin Pediatr 26:29–36CrossRef

10.

Towbin AJ, Meyers RL, Woodley H et al (2018) 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). Pediatr Radiol 48:1–19

11.

Uchida H, Sakamoto S, Sasaki K et al (2018) Surgical treatment strategy for advanced hepatoblastoma: resection versus transplantation. Pediatr Blood Cancer 65:e27383CrossRef

12.

Browne M, Sher D, Grant D et al (2008) Survival after liver transplantation for hepatoblastoma: a 2-center experience. J Pediatr Surg 43:1973–1981CrossRef

13.

Faraj W, Dar F, Marangoni G et al (2008) Liver transplantation for hepatoblastoma. Liver Transpl 14:1614–1619CrossRef

14.

Fuchs J, Cavdar S, Blumenstock G et al (2017) POST-TEXT III and IV hepatoblastoma: extended hepatic resection avoids liver transplantation in selected cases. Ann Surg 266:318–323CrossRef

15.

Lautz TB, Ben-Ami T, Tantemsapya N et al (2011) Successful nontransplant resection of POST-TEXT III and IV hepatoblastoma. Cancer 117:1976–1983CrossRef

16.

Tajiri T, Kimura O, Fumino S et al (2012) Surgical strategies for unresectable hepatoblastomas. J Pediatr Surg 47:2194–2198CrossRef

17.

Roebuck DJ, Aronson D, Clapuyt P et al (2007) 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol 37:123–132CrossRef

18.

József Z, Maibach R, Shafford E et al (2010) Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 28:2584–2590CrossRef

19.

López-Terrada D, Alaggio R, de Dávila MT et al (2014) Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium. Mod Pathol 27:472–491CrossRef

20.

Qiao GL, Li L, Cheng W et al (2014) Predictors of survival after resection of children with hepatoblastoma: a single Asian center experience. Eur J Surg Oncol 40:1533–1539CrossRef

21.

Aronson DC, Weeda VB, Maibach R et al (2019) Microscopically positive resection margin after hepatoblastoma resection: what is the impact on prognosis? A Childhood Liver Tumours Strategy Group (SIOPEL) report. Eur J Cancer 106:126–132CrossRef

22.

Meyers RL, Maibach R, Hiyama E et al (2017) Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. Lancet Oncol 18:122–131CrossRef

23.

Czauderna P, Haeberle B, Hiyama E et al (2016) The Children’s Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer 52:92–101CrossRef

24.

Katzenstein HM, Furman WL, Malogolowkin MH et al (2017) Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: a report from the Children’s Oncology Group AHEP0731 study committee. Cancer 123:2360–2367CrossRef

25.

Shanmugam N, Scott JX, Kumar V et al (2017) Multidisciplinary management of hepatoblastoma in children: experience from a developing country. Pediatr Blood Cancer 64:e26249CrossRef

26.

Haas RJD, Wicherts DA, Flores E et al (2008) R1 resection by necessity for colorectal liver metastases is it still a contraindication to surgery? Ann Surg 248:626–637PubMed

27.

Sakamoto S, Kasahara M, Mizuta K et al (2014) Nationwide survey of the outcomes of living donor liver transplantation for hepatoblastoma in Japan. Liver Transpl 20:333–346CrossRef

28.

Wang LL, Filippi RZ, Zurakowski D et al (2010) Effects of neoadjuvant chemotherapy on hepatoblastoma: a morphologic and immunohistochemical study. Am J Surg Pathol 34:287–299CrossRef

29.

Venkatramani R, Wang L, Malvar J et al (2012) Tumor necrosis predicts survival following neo-adjuvant chemotherapy for hepatoblastoma. Pediatr Blood Cancer 59:493–498CrossRef

30.

József Z, Laurence B, Penelope B et al (2013) Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol 14:834–842CrossRef

Title: Impact of microscopically margin-positive resection on survival in children with hepatoblastoma after hepatectomy: a retrospective cohort study
Authors: Xianghai Ren
Haibo Li
Mei Diao
Hang Xu
Long Li
Publication date: 01-04-2020
Publisher: Springer Singapore
Keywords: Metastasis
Cytostatic Therapy
Published in: International Journal of Clinical Oncology / Issue 4/2020
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01573-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2020

Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA

Predictive value of 18F-FDG PET/CT for acute exacerbation of interstitial lung disease in patients with lung cancer and interstitial lung disease treated with chemotherapy

Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei

Associations between expression levels of nine core nucleotide excision repair genes in lymphocytes and risk of head and neck squamous cell carcinomas in a Chinese population

HPV vaccination in Japan: can educational intervention promote a father’s intention to encourage his daughter’s vaccination?

Correction to: Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer